

# Yusuke Suzuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4348338/publications.pdf>

Version: 2024-02-01

122  
papers

3,957  
citations

147801

31  
h-index

144013

57  
g-index

124  
all docs

124  
docs citations

124  
times ranked

3050  
citing authors

#	ARTICLE	IF	CITATIONS
1	Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity. <i>Journal of Clinical Investigation</i> , 2009, 119, 1668-77.	8.2	356
2	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	5.2	325
3	Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. <i>JAMA Internal Medicine</i> , 2019, 179, 942.	5.1	266
4	Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. <i>Nature Medicine</i> , 2016, 22, 183-193.	30.7	161
5	Toll-Like Receptor 9 Affects Severity of IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 2384-2395.	6.1	160
6	IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. <i>Kidney International</i> , 2018, 93, 700-705.	5.2	151
7	Phenotype of asthma related with high serum periostin levels. <i>Allergology International</i> , 2015, 64, 175-180.	3.3	102
8	Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1315-1321.	0.7	99
9	A Panel of Serum Biomarkers Differentiates IgA Nephropathy from Other Renal Diseases. <i>PLoS ONE</i> , 2014, 9, e98081.	2.5	93
10	Toll-Like Receptor 9 Stimulation Induces Aberrant Expression of a Proliferation-Inducing Ligand by Tonsillar Germinal Center B Cells in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1227-1238.	6.1	91
11	A histologic classification of IgA nephropathy for predicting long-term prognosis: emphasis on end-stage renal disease. <i>Journal of Nephrology</i> , 2013, 26, 350-357.	2.0	88
12	TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy. <i>Kidney International</i> , 2020, 97, 340-349.	5.2	78
13	Changes in Nephritogenic Serum Galactose-Deficient IgA1 in IgA Nephropathy following Tonsillectomy and Steroid Therapy. <i>PLoS ONE</i> , 2014, 9, e89707.	2.5	72
14	Genome-Wide Scan in a Novel IgA Nephropathy Model Identifies a Susceptibility Locus on Murine Chromosome 10, in a Region Syntenic to Human IGAN1 on Chromosome 6q22-23. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1289-1299.	6.1	67
15	Serum levels of galactose-deficient immunoglobulin (Ig) A1 and related immune complex are associated with disease activity of IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 770-777.	1.6	59
16	Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A Nephropathy. <i>JAMA Network Open</i> , 2019, 2, e194772.	5.9	59
17	Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy. <i>PLoS ONE</i> , 2018, 13, e0190967.	2.5	56
18	Tonsillar TLR9 expression and efficacy of tonsillectomy with steroid pulse therapy in IgA nephropathy patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1090-1097.	0.7	55

#	ARTICLE	IF	CITATIONS
19	Development of a Model of Early-Onset IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1364-1374.	6.1	51
20	Expressions and Roles of Periostin in Otolaryngological Diseases. <i>Allergology International</i> , 2014, 63, 171-180.	3.3	49
21	Circulating TNF Receptors 1 and 2 Predict Mortality in Patients with End-stage Renal Disease Undergoing Dialysis. <i>Scientific Reports</i> , 2017, 7, 43520.	3.3	49
22	Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. <i>Kidney International Reports</i> , 2017, 2, 1194-1207.	0.8	49
23	Nationwide survey on current treatments for IgA nephropathy in Japan. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 827-833.	1.6	48
24	Circulating TNF Receptors 1 and 2 Are Associated with the Severity of Renal Interstitial Fibrosis in IgA Nephropathy. <i>PLoS ONE</i> , 2015, 10, e0122212.	2.5	48
25	Potential Immunopathogenic Role of the Mucosa-Bone Marrow Axis in IgA Nephropathy: Insights From Animal Models. <i>Seminars in Nephrology</i> , 2008, 28, 66-77.	1.6	43
26	Determination of Severity of Murine IgA Nephropathy by Glomerular Complement Activation by Aberrantly Glycosylated IgA and Immune Complexes. <i>American Journal of Pathology</i> , 2012, 181, 1338-1347.	3.8	42
27	A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. <i>Kidney International</i> , 2019, 96, 104-116.	5.2	41
28	Aberrant Glycosylation of IgA1 and Anti-Glycan Antibodies in IgA Nephropathy: Role of Mucosal Immune System. <i>Advances in Oto-Rhino-Laryngology</i> , 2011, 72, 60-63.	1.6	40
29	Proposal of remission criteria for IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2014, 18, 481-486.	1.6	38
30	Amelioration of Crescentic Glomerulonephritis by RhoA Kinase Inhibitor, Fasudil, through Podocyte Protection and Prevention of Leukocyte Migration. <i>American Journal of Pathology</i> , 2008, 172, 603-614.	3.8	35
31	Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool. <i>Kidney International</i> , 2020, 98, 1009-1019.	5.2	35
32	Pathological Role of Tonsillar B Cells in IgA Nephropathy. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	34
33	Circulating Tumor Necrosis Factor Receptors: A Potential Biomarker for the Progression of Diabetic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1957.	4.1	34
34	Quantifying Duration of Proteinuria Remission and Association with Clinical Outcome in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 436-447.	6.1	34
35	Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). <i>Clinical and Experimental Nephrology</i> , 2020, 24, 526-540.	1.6	33
36	Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy?. <i>Disease Markers</i> , 2016, 2016, 1-6.	1.3	32

#	ARTICLE	IF	CITATIONS
37	Association between circulating tumor necrosis factor-related biomarkers and estimated glomerular filtration rate in type 2 diabetes. <i>Scientific Reports</i> , 2018, 8, 15302.	3.3	30
38	The Mucosa-Bone-Marrow Axis in IgA Nephropathy. , 2007, 157, 70-79.		29
39	Clinical predictive biomarkers for normoalbuminuric diabetic kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2018, 141, 62-68.	2.8	29
40	Crucial Role of AIM/CD5L in the Development of Glomerular Inflammation in IgA Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2013-2024.	6.1	29
41	Chronic intermittent hypoxia-mediated renal sympathetic nerve activation in hypertension and cardiovascular disease. <i>Scientific Reports</i> , 2018, 8, 17926.	3.3	28
42	Different Pathological Roles of Toll-Like Receptor 9 on Mucosal B Cells and Dendritic Cells in Murine IgA Nephropathy. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-10.	3.3	26
43	Lipopolysaccharide-Deficient <i>Acinetobacter baumannii</i> Due to Colistin Resistance Is Killed by Neutrophil-Produced Lysozyme. <i>Frontiers in Microbiology</i> , 2020, 11, 573.	3.5	26
44	Nasal-associated lymphoid tissue is the major induction site for nephritogenic IgA in murine IgA nephropathy. <i>Kidney International</i> , 2021, 100, 364-376.	5.2	25
45	Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. <i>Kidney International</i> , 2022, 102, 160-172.	5.2	25
46	Development of animal models of human IgA nephropathy. <i>Drug Discovery Today: Disease Models</i> , 2014, 11, 5-11.	1.2	24
47	Pathogenic Role of a Proliferation-Inducing Ligand (APRIL) in Murine IgA Nephropathy. <i>PLoS ONE</i> , 2015, 10, e0137044.	2.5	24
48	Murine Models of Human IgA Nephropathy. <i>Seminars in Nephrology</i> , 2018, 38, 513-520.	1.6	23
49	IgA Nephropathy Benefits from Compound K Treatment by Inhibiting NF- $\kappa$ B/NLRP3 Inflammasome and Enhancing Autophagy and SIRT1. <i>Journal of Immunology</i> , 2020, 205, 202-212.	0.8	22
50	Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. <i>Clinical and Experimental Nephrology</i> , 2018, 22, 1266-1280.	1.6	21
51	Dietary Zinc Is a Key Environmental Modifier in the Progression of IgA Nephropathy. <i>PLoS ONE</i> , 2014, 9, e90558.	2.5	19
52	Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. <i>Neuroscience Letters</i> , 2015, 593, 51-55.	2.1	19
53	Evaluation of Long-Term Combination Therapy With Peritoneal Dialysis and Hemodialysis. <i>Therapeutic Apheresis and Dialysis</i> , 2017, 21, 180-184.	0.9	19
54	A grading system that predicts the risk of dialysis induction in IgA nephropathy patients based on the combination of the clinical and histological severity. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 16-25.	1.6	18

#	ARTICLE	IF	CITATIONS
55	Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 316-322.	1.6	18
56	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. <i>Kidney International Reports</i> , 2022, 7, 993-1003.	0.8	18
57	Diagnosis and activity assessment of immunoglobulin A nephropathy: current perspectives on noninvasive testing with aberrantly glycosylated immunoglobulin A-related biomarkers. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 409.	1.8	17
58	COVID-19-induced acute renal tubular injury associated with elevation of serum inflammatory cytokine. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 1240-1246.	1.6	16
59	IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination. <i>Internal Medicine</i> , 2022, 61, 1033-1037.	0.7	16
60	TWEAK/Fn14 system and crescent formation in IgA nephropathy. <i>BMC Nephrology</i> , 2015, 16, 27.	1.8	15
61	Galactose-deficient IgA1 in skin and serum from patients with skin-limited and systemic IgA vasculitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1078-1085.	1.2	15
62	The Phenotypic Difference of IgA Nephropathy and its Race/Gender-dependent Molecular Mechanisms. <i>Kidney360</i> , 2021, 2, 1339-1348.	2.1	15
63	The Kinetics of Glomerular Deposition of Nephritogenic IgA. <i>PLoS ONE</i> , 2014, 9, e113005.	2.5	13
64	Reevaluation of the Mucosa-Bone Marrow Axis in IgA Nephropathy with Animal Models. <i>Advances in Oto-Rhino-Laryngology</i> , 2011, 72, 64-67.	1.6	12
65	Experimental evidence of cell dissemination playing a role in pathogenesis of IgA nephropathy in multiple lymphoid organs. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 320-326.	0.7	12
66	Human bronchial smooth muscle cell proliferation via thromboxane A2 receptor. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2004, 71, 375-382.	2.2	11
67	Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy. <i>BMC Nephrology</i> , 2014, 15, 89.	1.8	11
68	High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 145-154.	4.8	11
69	Suffocation due to Acute Airway Edema in a Patient with Hereditary Angioedema Highlighted the Need for Urgent Improvements in Treatment Availability in Japan. <i>Internal Medicine</i> , 2018, 57, 3193-3197.	0.7	11
70	Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases. <i>BMC Nephrology</i> , 2020, 21, 402.	1.8	11
71	Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy. <i>CEN Case Reports</i> , 2021, 10, 17-22.	0.9	11
72	The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its Anti-Inflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3967.	4.1	10

#	ARTICLE	IF	CITATIONS
73	Exercise-Induced Acute Kidney Injury in a Police Officer with Hereditary Renal Hypouricemia. Case Reports in Nephrology and Dialysis, 2019, 9, 92-101.	0.6	10
74	Emergent initiation of dialysis is related to an increase in both mortality and medical costs. Scientific Reports, 2020, 10, 19638.	3.3	10
75	Are there animal models of IgA nephropathy?. Seminars in Immunopathology, 2021, 43, 639-648.	6.1	10
76	Roles of Bone Marrow, Mucosa and Lymphoid Tissues in Pathogenesis of Murine IgA Nephropathy. , 2007, 157, 164-168.		9
77	Amelioration of Angiotensin II-induced Salt-Sensitive Hypertension by Liver-Type Fatty Acid-binding Protein in Proximal Tubules. Hypertension, 2013, 62, 712-718.	2.7	9
78	Paradigm shift in activity assessment of IgA nephropathy – optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting. Expert Opinion on Biological Therapy, 2015, 15, 583-593.	3.1	9
79	Galactose-Deficient IgA1-Specific Antibody Recognizes GalNAc-Modified Unique Epitope on Hinge Region of IgA1. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2018, 37, 252-256.	1.6	9
80	Establishment of a novel mouse xenograft model of human uterine leiomyoma. Scientific Reports, 2018, 8, 8872.	3.3	9
81	Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function. Journal of Diabetes Investigation, 2021, 12, 382-389.	2.4	9
82	High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 76, 42-48.	4.8	8
83	Association between social frailty as well as early physical dysfunction and exercise intolerance among older patients receiving hemodialysis. Geriatrics and Gerontology International, 2021, 21, 664-669.	1.5	8
84	Continuous extracorporeal treatments in a dialysis patient with COVID-19. CEN Case Reports, 2021, 10, 172-177.	0.9	7
85	Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice. Scientific Reports, 2021, 11, 1194.	3.3	7
86	Uncoupling of Glomerular IgA Deposition and Disease Progression in Alymphoplasia Mice with IgA Nephropathy. PLoS ONE, 2014, 9, e95365.	2.5	6
87	Enrichment of airborne Japanese cedar ( <i>Cryptomeria japonica</i> ) pollen in mountain ranges when passing through a front accompanying temperate low pressure. Aerobiologia, 2018, 34, 105-110.	1.7	6
88	Expression of Cathepsin L and Its Intrinsic Inhibitors in Glomeruli of Rats With Puromycin Aminonucleoside Nephrosis. Journal of Histochemistry and Cytochemistry, 2018, 66, 863-877.	2.5	6
89	Efficacy of endoscopic sinus surgery for eosinophilic chronic rhinosinusitis with asthma. Allergy International, 2020, 69, 144-145.	3.3	6
90	Better remission rates in elderly Japanese patients with primary membranous nephropathy in nationwide real-world practice: The Japan Nephrotic Syndrome Cohort Study (JNSCS). Clinical and Experimental Nephrology, 2020, 24, 893-909.	1.6	6

#	ARTICLE	IF	CITATIONS
91	Galactose-deficient IgA1 and nephritis-associated plasmin receptors as markers for IgA-dominant infection-related glomerulonephritis. <i>Medicine (United States)</i> , 2021, 100, e24460.	1.0	6
92	Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3173.	2.4	6
93	Rapid progression to end-stage renal disease in a child with IgA-dominant infection-related glomerulonephritis associated with parvovirus B19. <i>CEN Case Reports</i> , 2020, 9, 423-430.	0.9	5
94	LCC18 , a benzamide-linked small molecule, ameliorates IgA nephropathy in mice. <i>Journal of Pathology</i> , 2021, 253, 427-441.	4.5	5
95	Association Between Kidney Function Decline and Baseline TNFR Levels or Change Ratio in TNFR by Febuxostat Chiefly in Non-diabetic CKD Patients With Asymptomatic Hyperuricemia. <i>Frontiers in Medicine</i> , 2021, 8, 634932.	2.6	5
96	Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes. <i>Frontiers in Endocrinology</i> , 2022, 13, 849457.	3.5	5
97	Impact of the number of steroid pulses in tonsillectomy combined with steroid pulse therapy: a nationwide retrospective study in Japan. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 19-27.	1.6	4
98	Multi-point analysis of airborne Japanese cedar ( <i>Cryptomeria japonica</i> D. Don) pollen by Pollen Robo and the relationship between pollen count and the severity of symptoms. <i>Aerobiologia</i> , 2019, 35, 635-646.	1.7	3
99	Utility of remission criteria for the renal prognosis of IgA nephropathy. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 988-995.	1.6	3
100	Predictors of early remission of proteinuria in adult patients with minimal change disease: a retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
101	Carbon Ion Beam Radiotherapy for Sinonasal Malignant Tumors Invading Skull Base. <i>Case Reports in Otolaryngology</i> , 2014, 2014, 1-4.	0.2	2
102	208. GALACTOSE DEFICIENT IGA1 (GD-IGA1) IN SKIN AND SERUM FROM PATIENTS WITH SKIN-LIMITED AND SYSTEMIC IGA VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	1.9	2
103	A case of hereditary angioedema due to C1-inhibitor deficiency with recurrent abdominal pain diagnosed 40 years after the occurrence of the initial symptom. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1175-1179.	0.8	2
104	Negative-pressure wound therapy is effective for peritoneal dialysis catheter exit-site management in the early postoperative period. <i>Scientific Reports</i> , 2022, 12, 70.	3.3	2
105	Association of cardiac autonomic neuropathy assessed by heart rate response during exercise with intradialytic hypotension and mortality in hemodialysis patients. <i>Kidney International</i> , 2022, 101, 1054-1062.	5.2	2
106	Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia. <i>Journal of Onco-Nephrology</i> , 2020, 4, 41-45.	0.6	1
107	Effect of blood volume change related to intensity of intradialytic aerobic exercise on hemodialysis adequacy: a pilot study. <i>International Urology and Nephrology</i> , 2021, , 1.	1.4	1
108	A Case of Cerebellar Ataxia with EB Virus Infection. <i>Practica Otologica, Supplement</i> , 2011, 130, 124-130.	0.0	1

#	ARTICLE	IF	CITATIONS
109	Coronary Artery Bypass Grafting in Patients with Chronic Kidney Disease: Chronic Kidney Disease Has an Independent Adverse Effect on the Long-Term Outcome of Coronary Artery Bypass Grafting. <i>BioMed Research International</i> , 2022, 2022, 1-14.	1.9	1
110	FC051: Atacicept Reduces Serum ANTI-GD-IGA1 Levels in IgAN Patients. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	1
111	FP304ABERRANT APRIL EXPRESSION IN TONSILLAR GERMINAL CENTER B CELLS IN IGA NEPHROPATHY PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii168-iii169.	0.7	0
112	P0350THE DURATION OF PROTEINURIA REMISSION AND CLINICAL OUTCOMES IN IGA NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
113	P0505COST ANALYSIS OF SCREENING FOR IGA NEPHROPATHY USING NOVEL BIOMARKERS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
114	Ischemic Stroke Induces Rapid Renal Oxidative Stress and Lipometabolic Change. <i>Juntendo Medical Journal</i> , 2021, 67, 39-45.	0.1	0
115	Th2 cytokine induces aberrant O-glycosylation in the hinge region of IgA1 via downregulation of core1 $\beta$ 1, 3-galactosyltransferase and its molecular chaperone Cosmc. <i>Juntendo J. Igaku</i> , 2007, 53, 113-120.	0.1	0
116	A Case of Piriform Sinus Fistula Occurring Seven Times before Resolution. <i>Practica Otologica, Supplement</i> , 2011, 130, 106-111.	0.0	0
117	Prophylactic Effect and QOL in Cases of Japanese Cedar Pollinosis. <i>Practica Otologica, Supplement</i> , 2011, 130, 44-48.	0.0	0
118	Two Cases of Maxillary Sinus Hematocele Mimicking Malignant Tumors. <i>Practica Otologica, Supplement</i> , 2011, 130, 49-55.	0.0	0
119	Clinical Study of 80 Parotid Gland Tumors. <i>Practica Otologica, Supplement</i> , 2011, 130, 146-151.	0.0	0
120	A Case of Papillary Carcinoma from a Thyroglossal Duct Remnant. <i>Practica Otologica, Supplement</i> , 2011, 130, 184-189.	0.0	0
121	Beyond the Differences in Tonsillectomy in IgA Nephropathy: From Rationale To Indications in Patients. , 2016, , 311-319.		0
122	17. Novel Therapeutic Approaches Based on Recent Advance in Elucidation of Pathogenesis of IgA Nephropathy. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 1976-1982.	0.0	0